-
Something wrong with this record ?
Pharmacogenetics of dabigatran and apixaban in association with gastrointestinal bleeding
T. Veleta, M. Beranek, I. Tacheci, P. Dulicek, R. Maly, E. Cermakova, T. Soukup
Language English Country Sweden
Document type Journal Article
PubMed
39688660
Knihovny.cz E-resources
- MeSH
- Antithrombins adverse effects therapeutic use MeSH
- Dabigatran * adverse effects MeSH
- Adult MeSH
- Pharmacogenetics MeSH
- Gastrointestinal Hemorrhage * genetics chemically induced MeSH
- Genotype MeSH
- Factor Xa Inhibitors adverse effects therapeutic use MeSH
- Polymorphism, Single Nucleotide * MeSH
- Middle Aged MeSH
- Humans MeSH
- ATP Binding Cassette Transporter, Subfamily B MeSH
- Pyrazoles * adverse effects therapeutic use MeSH
- Pyridones * adverse effects therapeutic use MeSH
- Aged, 80 and over MeSH
- Aged MeSH
- Check Tag
- Adult MeSH
- Middle Aged MeSH
- Humans MeSH
- Male MeSH
- Aged, 80 and over MeSH
- Aged MeSH
- Female MeSH
- Publication type
- Journal Article MeSH
OBJECTIVES: To determine whether selected single nucleotide polymorphisms (SNPs) of genes encoding proteins responsible for the activation, transport, or metabolism of dabigatran and apixaban might be associated with a risk of gastrointestinal bleeding in a cohort of adult patients treated with these drugs. No previous study has focused specifically on the association with gastrointestinal bleeding. MATERIALS AND METHODS: Ninety-one patients treated with dabigatran or apixaban were genotyped for selected polymorphisms. The following polymorphisms were studied: ABCB1 gene rs1045642, rs4148738, rs1128503 and rs2032582; CES1 gene rs2244613, rs8192935 and rs2244614; and SULT1A1 gene rs9282861 and SULT1A2 gene rs1136703. Two groups divided by particular drugs and genotypes were compared in terms of the presence (bleeding group) or absence (nonbleeding group) of gastrointestinal bleeding. The genotype distribution was expressed via dominant and recessive models. RESULTS: In patients treated either with dabigatran or with apixaban, no evidence was found to support the association of gastrointestinal bleeding with any genotype for any of the studied SNPs. CONCLUSION: In both dabigatran- and apixaban-treated patients, no associations between the selected polymorphisms and gastrointestinal bleeding risk were found, however the results should be interpreted with caution because of the small cohort size.
- 000
- 00000naa a2200000 a 4500
- 001
- bmc25003363
- 003
- CZ-PrNML
- 005
- 20250206104307.0
- 007
- ta
- 008
- 250121s2024 sw f 000 0|eng||
- 009
- AR
- 035 __
- $a (PubMed)39688660
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a sw
- 100 1_
- $a Veleta, Tomas $u Department of Emergency Medicine, University Hospital Hradec Kralove and Faculty of Medicine, Hradec Kralove, Charles University, Czech Republic
- 245 10
- $a Pharmacogenetics of dabigatran and apixaban in association with gastrointestinal bleeding / $c T. Veleta, M. Beranek, I. Tacheci, P. Dulicek, R. Maly, E. Cermakova, T. Soukup
- 520 9_
- $a OBJECTIVES: To determine whether selected single nucleotide polymorphisms (SNPs) of genes encoding proteins responsible for the activation, transport, or metabolism of dabigatran and apixaban might be associated with a risk of gastrointestinal bleeding in a cohort of adult patients treated with these drugs. No previous study has focused specifically on the association with gastrointestinal bleeding. MATERIALS AND METHODS: Ninety-one patients treated with dabigatran or apixaban were genotyped for selected polymorphisms. The following polymorphisms were studied: ABCB1 gene rs1045642, rs4148738, rs1128503 and rs2032582; CES1 gene rs2244613, rs8192935 and rs2244614; and SULT1A1 gene rs9282861 and SULT1A2 gene rs1136703. Two groups divided by particular drugs and genotypes were compared in terms of the presence (bleeding group) or absence (nonbleeding group) of gastrointestinal bleeding. The genotype distribution was expressed via dominant and recessive models. RESULTS: In patients treated either with dabigatran or with apixaban, no evidence was found to support the association of gastrointestinal bleeding with any genotype for any of the studied SNPs. CONCLUSION: In both dabigatran- and apixaban-treated patients, no associations between the selected polymorphisms and gastrointestinal bleeding risk were found, however the results should be interpreted with caution because of the small cohort size.
- 650 _2
- $a lidé $7 D006801
- 650 12
- $a dabigatran $x škodlivé účinky $7 D000069604
- 650 12
- $a pyrazoly $x škodlivé účinky $x terapeutické užití $7 D011720
- 650 12
- $a pyridony $x škodlivé účinky $x terapeutické užití $7 D011728
- 650 _2
- $a mužské pohlaví $7 D008297
- 650 12
- $a gastrointestinální krvácení $x genetika $x chemicky indukované $7 D006471
- 650 _2
- $a ženské pohlaví $7 D005260
- 650 12
- $a jednonukleotidový polymorfismus $7 D020641
- 650 _2
- $a senioři $7 D000368
- 650 _2
- $a lidé středního věku $7 D008875
- 650 _2
- $a antitrombiny $x škodlivé účinky $x terapeutické užití $7 D000991
- 650 _2
- $a genotyp $7 D005838
- 650 _2
- $a farmakogenetika $7 D010597
- 650 _2
- $a senioři nad 80 let $7 D000369
- 650 _2
- $a inhibitory faktoru Xa $x škodlivé účinky $x terapeutické užití $7 D065427
- 650 _2
- $a dospělí $7 D000328
- 650 _2
- $a P-glykoproteiny $7 D018435
- 655 _2
- $a časopisecké články $7 D016428
- 700 1_
- $a Beranek, Martin $u Institute of Clinical Biochemistry and Diagnostics, University Hospital Hradec Kralove and Faculty of Medicine, Hradec Kralove, Charles University, Czech Republic $u Department of Biochemical Sciences, Faculty of Pharmacy, Hradec Kralove, Charles University, Czech Republic
- 700 1_
- $a Tacheci, Ilja $u 2nd Department of Internal Medicine - Gastroenterology, University Hospital Hradec Kralove and Faculty of Medicine, Hradec Kralove, Charles University, Czech Republic
- 700 1_
- $a Dulicek, Petr $u 4th Department of Internal Medicine - Haematology, University Hospital Hradec Kralove and Faculty of Medicine, Hradec Kralove, Charles University, Czech Republic
- 700 1_
- $a Maly, Radovan $u 1st Department of Internal Medicine - Cardioangiology, University Hospital Hradec Kralove and Faculty of Medicine, Hradec Kralove, Charles University, Czech Republic
- 700 1_
- $a Cermakova, Eva $u Department of Medical Biophysics, Faculty of Medicine, Hradec Kralove, Charles University, Czech Republic
- 700 1_
- $a Soukup, Tomas $u 2nd Department of Internal Medicine - Gastroenterology, University Hospital Hradec Kralove and Faculty of Medicine, Hradec Kralove, Charles University, Czech Republic
- 773 0_
- $w MED00168352 $t Neuro-endocrinology letters $x 2354-4716 $g Roč. 45, č. 5 (2024), s. 333-340
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/39688660 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y - $z 0
- 990 __
- $a 20250121 $b ABA008
- 991 __
- $a 20250206104303 $b ABA008
- 999 __
- $a ok $b bmc $g 2263252 $s 1239370
- BAS __
- $a 3
- BAS __
- $a PreBMC-MEDLINE
- BMC __
- $a 2024 $b 45 $c 5 $d 333-340 $e 20241128 $i 2354-4716 $m Neuro-endocrinology letters $n Neuro Endocrinol Lett $x MED00168352
- LZP __
- $a Pubmed-20250121
